BFRA - Biofrontera AG

NasdaqCM - NasdaqCM Real-time price. Currency in USD
13.29
-0.16 (-1.19%)
At close: 12:32PM EST
Stock chart is not supported by your current browser
Previous close13.45
Open13.82
Bid0.00 x 800
Ask0.00 x 1100
Day's range13.29 - 13.67
52-week range11.04 - 17.98
Volume17,061
Avg. volume1,632
Market cap290.041M
Beta (3Y monthly)0.54
PE ratio (TTM)N/A
EPS (TTM)-0.76
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est20.83
Trade prices are not sourced from all markets
  • GlobeNewswire12 days ago

    Biofrontera receives FDA approval for upscaling of batch size for Ameluz® production

    Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA), and earlier the European Medicines Agency (EMA), have approved the upscaling of the batch size for the production of Ameluz® to 35 kg from previously 7 kg. “The approval for a 5-fold increase in batch size ensures a secure supply of Ameluz® to meet the growing demand for Ameluz® in all regions.

  • GlobeNewswire24 days ago

    Ruling by the U.S. District Court of Massachussetts

    Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today comments on a court order issued by the U.S. District Court of Massachussetts. Biofrontera is currently involved in litigation with DUSA Pharmaceuticals. DUSA sued Biofrontera in the U.S. District Court of Massachusetts.

  • GlobeNewswire2 months ago

    Biofrontera reports earnings results for the third quarter and first nine months of 2018

    Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2018 and provided an update on recent developments. Total revenue increased 98% to approximately EUR 14.6 million for the first nine months of 2018, compared to approximately EUR 7.3 million in the same period 2017. Product revenue increased 131% to approximately EUR 14.4 million for the first nine months of 2018, compared to approximately EUR 6.2 million in the same period 2017.

  • GlobeNewswire2 months ago

    Biofrontera Announces Conference Call to Discuss Q3 2018 Financial Results

    Leverkusen, Germany, Nov. 05, 2018 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be.

  • GlobeNewswire4 months ago

    Swissmedic approves Ameluz® in combination with daylight photodynamic therapy in Switzerland

    Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, announced today that Swissmedic, the Swiss national approval and supervisory authority for drugs and medical products, has approved the extension of the label of Ameluz® to its use in combination with photodynamic daylight therapy (daylight-PDT). The Swiss approval of Ameluz® with daylight-PDT follows the EU approval by the European Commission in March 2018. Ameluz is marketed in Switzerland by Louis Widmer, which also functions as local marketing authorization holder.